Navigation Links
Invest in a future without dementia
Date:6/18/2008

Alzheimer's Australia today, released a report 'Australian Dementia Research' that recommends annual funding for dementia research be increased three-fold to $36 million in response to the growing economic and social impact of the dementia epidemic.

Prepared by the Dementia Collaborative Research Centre at the University of NSW, the report concludes that current investment over the last six years in dementia research was about $13 million, 0.6% of the total direct costs of the condition. It recommends investment in dementia research should be maintained at 1.5% of the direct cost of dementia to keep pace with the increasing costs of treatment and care.

By 2030, the total cost to the health care system of dementia is projected to rise to $8.2 billion and the number of people with dementia to double to more than 460,000.

The report concludes that dementia research in Australia is significantly under funded in relation to other chronic diseases. According to 2003 figures, dementia funding is 50% of research funding for cancer, relative to the current disease burden and 30% of research funding for cardiovascular disease, relative to current direct cost of care.

Professor Henry Brodaty, one of the authors of the report, said, "Australian dementia researchers have an excellent track record not withstanding inadequate funding for dementia research."

"The recent initiatives taken by the Federal Government in establishing three Dementia Collaborative Research Centres and a program of dementia grants are encouraging. However, investment in dementia research falls short of what is needed if more effective medical interventions are to be provided to the ever increasing number of people at risk of dementia or with a diagnosis of dementia", he said.

"There is a strong case for dementia to be recognised by the National Health and Medical Research Council as a National Health Priority Area."

Glenn Rees, National Executive Director of Alzheimer's Australia said, "modelling done by Access Economics shows if the onset of Alzheimer's disease could be delayed by five years, it would result in a 50% reduction of new cases each year with a significant saving to the direct cost of dementia".

He said, "This emphasises the importance of research strategies directed to early diagnosis and identifying those at most risk of dementia. In this way Australians will have earlier access to medications currently being trialled that hold out the prospect of modifying the disease."

Projects like the CSIRO Australian Imaging Biomarker and Lifestyle Flagship Study of Ageing (AIBL) "are a strong indication of the potential of Australian research to make a significant contribution to global research in key areas such as early diagnosis and reducing the risk of dementia," he said.

"There is a window of opportunity if investment in research is increased. This will address the issues that the growing numbers of people with dementia will pose for the health system within 15 years".


'/>"/>

Contact: Kaylia Dunstan
61-407-232-212
Research Australia
Source:Eurekalert

Related medicine news :

1. Rutgers scientist receives prestigious Young Investigator Award
2. Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research
3. CIT GAP Funds Invests in OTraces, Inc.
4. Cardiva Medical, Inc. to Present at the Investment In Innovation (In3) Medical Device Summit on June 18, 2008 in San Francisco, CA; Announces the Completion of Its Latest Phase in Its US Sales Force Expansion
5. Digirad Corporation to Present at CapStone Small-Cap Investor Conference
6. Winning Method - Effective Identification and Development of Clinical Investigators
7. Case Western Reserve and Penn State investigators inhibit corneal inflammation
8. LA BioMed investigator wins Distinguished Educator Award
9. New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water
10. Carriage Services Updates Company & Investment Profile
11. White Ribbon Alliance for Safe Motherhood Challenges World Economic Forum on Africa to Invest in Womens Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
(Date:10/12/2017)... ... 12, 2017 , ... Farm Forward joins Bon ... leading institutions in announcing the launch of the Leadership Circle , a ... are raised for food. , Founding members of the Leadership Circle also include ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: